DEPARTMENT OF HEALTH AND HUMAN SERVICES

Indian Health Service

Request for Public Comment: 60-Day Proposed Information Collection: Application for Participation in the IHS Scholarship Program

AGENCY: Indian Health Service, HHS.

ACTION: Notice.

SUMMARY: In compliance with section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 which requires 60 days for public comment on proposed information collection projects, the Indian Health Service (IHS) is publishing for comment a summary of a proposed information collection to be submitted to the Office of Management and Budget (OMB) for review.


Reporting formats are contained in an IHS Scholarship Program application booklet.

Need and Use of Information Collection: The IHS Scholarship Branch needs this information for program administration and uses the information to solicit, process, and award IHS Pre- graduate, Preparatory, and/or Health Professions Scholarship grants and monitor the academic performance of awardees and to place awardees at payback sites. The IHS Scholarship Program is streamlining the application to reduce the time needed by applicants to complete and provide the information.

The IHS Scholarship Program plans on using information technology to make the application electronically available on the internet.

Affected Public: Individuals, not-for-profit institutions and State, local or tribal government. Type of Respondents: Students pursuing health care professions.

The table below provides: Types of data collection instruments, Estimated number of respondents, Number of responses per respondent, Annual number of responses, Average burden hour per response, and Total annual burden hour(s).

<table>
<thead>
<tr>
<th>Data collection instruments(s)</th>
<th>Number of respondents</th>
<th>Responses per respondent</th>
<th>Total annual response</th>
<th>Burden hour per response *</th>
<th>Annual burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scholarship Application (IHS–856)</td>
<td>1500</td>
<td>1</td>
<td>1500</td>
<td>1.00 (60 min)</td>
<td>1500</td>
</tr>
<tr>
<td>Checklist (856–2)</td>
<td>1500</td>
<td>1</td>
<td>1500</td>
<td>0.70 (42 min)</td>
<td>1050</td>
</tr>
<tr>
<td>Course Verification (856–3)</td>
<td>1500</td>
<td>1</td>
<td>1500</td>
<td>0.83 (50 min)</td>
<td>2490</td>
</tr>
<tr>
<td>Faculty/Employer Application (856–4)</td>
<td>1500</td>
<td>2</td>
<td>3000</td>
<td>0.75 (45 min)</td>
<td>1125</td>
</tr>
<tr>
<td>Justification (856–5)</td>
<td>1500</td>
<td>1</td>
<td>1500</td>
<td>0.13 (8 min)</td>
<td>195</td>
</tr>
<tr>
<td>Federal Debt (856–6)</td>
<td>1500</td>
<td>1</td>
<td>1500</td>
<td>0.83 (50 min)</td>
<td>21</td>
</tr>
<tr>
<td>Job Experience (856–7)</td>
<td>25</td>
<td>1</td>
<td>25</td>
<td>0.13 (8 min)</td>
<td>84</td>
</tr>
<tr>
<td>Accept/Denial (856–8)</td>
<td>650</td>
<td>1</td>
<td>650</td>
<td>0.03 (2 min)</td>
<td>45</td>
</tr>
<tr>
<td>Receipt of Application (818)</td>
<td>1500</td>
<td>1</td>
<td>1500</td>
<td>0.02 (1 min)</td>
<td>25</td>
</tr>
<tr>
<td>Address Change Notice (816)</td>
<td>25</td>
<td>1</td>
<td>25</td>
<td>0.05 (3 min)</td>
<td>43</td>
</tr>
<tr>
<td>Scholarship Program Agreement (817)</td>
<td>850</td>
<td>1</td>
<td>850</td>
<td>0.05 (3 min)</td>
<td>33</td>
</tr>
<tr>
<td>Health Professions Contract (818)</td>
<td>650</td>
<td>1</td>
<td>650</td>
<td>0.13 (8 min)</td>
<td>169</td>
</tr>
<tr>
<td>Stipend Check (D–02)</td>
<td>100</td>
<td>1</td>
<td>100</td>
<td>0.13 (8 min)</td>
<td>13</td>
</tr>
<tr>
<td>Enrollment (F–02)</td>
<td>1300</td>
<td>1</td>
<td>1300</td>
<td>0.18 (11 min)</td>
<td>45</td>
</tr>
<tr>
<td>Academic Problem/Change (F–04)</td>
<td>50</td>
<td>1</td>
<td>50</td>
<td>0.13 (8 min)</td>
<td>6</td>
</tr>
<tr>
<td>Request Assistance (G–02)</td>
<td>217</td>
<td>1</td>
<td>217</td>
<td>0.13 (8 min)</td>
<td>28</td>
</tr>
<tr>
<td>Summer School (G–04)</td>
<td>193</td>
<td>1</td>
<td>193</td>
<td>0.10 (6 min)</td>
<td>19</td>
</tr>
<tr>
<td>Placement (H–07)</td>
<td>250</td>
<td>1</td>
<td>250</td>
<td>0.17 (10 min)</td>
<td>43</td>
</tr>
<tr>
<td>Graduation (H–08)</td>
<td>250</td>
<td>1</td>
<td>250</td>
<td>0.13 (8 min)</td>
<td>20</td>
</tr>
<tr>
<td>Site Preference (J–04)</td>
<td>150</td>
<td>1</td>
<td>150</td>
<td>0.10 (6 min)</td>
<td>15</td>
</tr>
<tr>
<td>Travel Reimb (J–05)</td>
<td>150</td>
<td>1</td>
<td>150</td>
<td>0.25 (15 min)</td>
<td>63</td>
</tr>
<tr>
<td>Status Report (K–03)</td>
<td>250</td>
<td>1</td>
<td>250</td>
<td>0.75 (45 min)</td>
<td>150</td>
</tr>
<tr>
<td>Preferred Assignment (K–04)</td>
<td>200</td>
<td>1</td>
<td>200</td>
<td>0.13 (8 min)</td>
<td>3</td>
</tr>
<tr>
<td>Request of Deferment (L–03)</td>
<td>20</td>
<td>1</td>
<td>20</td>
<td>0.13 (8 min)</td>
<td>3</td>
</tr>
</tbody>
</table>

Total | 15,830 | | | | 7,380 |

*For ease of understanding, burden hours are also provided in actual minutes.

There are no Capital Costs, Operating Costs, and/or Maintenance Costs to report.

Request for Comments: Your written comments and/or suggestions are invited on one or more of the following points: (a) Whether the information collection activity is necessary to carry out an agency function; (b) whether the agency processes the information collected in a useful and timely fashion; (c) the accuracy of public burden estimate (the estimated amount of time needed for individual respondents to provide the requested information); (d)
whether the methodology and assumptions used to determine the estimates are logical; (e) ways to enhance the quality, utility, and clarity of the information being collected; and (f) ways to minimize the public burden through the use of automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

Send Comments and Requests for Further Information: Send your written comments, requests for more information on the proposed collection, or requests to obtain a copy of the data collection instrument(s) and instructions to: Mrs. Chris Rouleau, IHS Reports Clearance Officer, 801 Thompson Ave., Suite 450, Rockville, MD 20852–1601; call non-toll free (301) 443–5938; send via facsimile to (301) 443–2316; or send your e-mail requests, comments, and return address to: Christina.Rouleau@ihs.gov.

Comment Due Date: Your comments regarding this information collection are best assured of having full effect if received within 60 days of the date of this publication.


Charles W. Grim,
Assistant Surgeon General, Director, Indian Health Service.

[FR Doc. 07–3895 Filed 8–9–07; 8:45 am]

BILLING CODE 4165–16–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESS: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Treatment for Cystic Fibrosis Cells and Other Reduced Cl—Conductance Cells

Description of Technology: Cystic fibrosis is the most common fatal genetic disease among Caucasians. It is caused by a defect in the cystic fibrosis transmembrane regulator (CFTR) protein. A normal CFTR transports chloride ions across the membrane of epithelial cells lining several organs in the body such as the lungs and the pancreas. The most debilitating consequence of the defective CFTR protein occurs in the lungs of cystic fibrosis patients, where insufficient chloride transport prevents water from exiting epithelial cells. This causes the lungs to produce abnormally thick, sticky mucus that clogs the airways and leads to fatal lung infections. Currently there is no cure for the disease. Present treatments result in undesirable side effects such as cardiac, renal, and/or central nervous system tissue. The NIH has developed a method of identifying cystic fibrosis transmembrane regulator binding compounds for treating cells having a reduced Cl—conductance, such as cystic fibrosis cells. It has also identified a compound, 1,3-Diallyl-8-cyclohexylxanthine (DAX), for potential treatment of cystic fibrosis. Because DAX has specificity in target areas of activity, treatment with this compound can potentially prevent all of the complications of cystic fibrosis including the production of abnormal mucus and without undesired side effects. DAX is active in extremely low concentrations.

Applications: Diagnostic; Therapeutic agent for the treatment of cells having a reduced Cl—conductance.

Market: This is intended for cystic fibrosis or other reduced Cl—conductance cells; Approximately 70,000 children and young adults worldwide, including 30,000 in the U.S. and 30,000 in Europe.

Development Status: Dr. Pollard has performed pre-clinical testing.

Inventors: Dr. Harvey B. Pollard and Dr. Kenneth A. Jacobson (NIDDK).

Publications:


Foreign patent rights available.

Licensing Status: Available for exclusive or non-exclusive licensing.

Licensing Contact: Catherine A. Wendelken; 301/435–5282; wendelkenc@od.nih.gov.


Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. E7–15622 Filed 8–9–07; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Research Program Project on Hypertension in Youth.

Date: September 7, 2007.

Time: 8 a.m. to 1 p.m.

Agenda: To review and evaluate grant applications.

Place: Double Tree Washington, 1515 Rhode Island Ave., NW., Washington, DC 20005.

Contact Person: Holly Patton, PhD, Scientific Review Administrator, Review